[A23-133] Cipaglucosidase alfa (Pompe disease) – Addendum to Project A23-79
Last updated 01.02.2024
Project no.:
A23-133
Commission:
Commission awarded on 12.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adults with late-onset Pompe disease (LOPD) (acid α-glucosidase [GAA] deficiency)
After addendum now: indication of minor added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A23-133
| Project no. | Title | Status |
|---|---|---|
| A23-79 | Cipaglucosidase alfa (Pompe disease) – Benefit assessment according to § 35a Social Code Book (SGB) V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-01 A G-BA decision was published.